|
Jul 18
|
Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration
|
|
Jul 16
|
Top 3 Stocks on SEHK Possibly Trading Below Estimated Value in July 2024
|
|
Jul 15
|
Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
|
|
Dec 27
|
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients
|
|
Dec 4
|
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
|
|
Nov 30
|
Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis
|
|
Nov 29
|
Everest Medicines Announces Acceptance of Nefecon® New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea
|